Friday, 23 Aug 2019

You are here

RheumNow Week in Review - 15 April 2016

Video recap of highlights from this week at

  1. In patients with connective tissue disease and interstitial lung disease (ILD): NSIP, UIP, OP (use to be BOOP), LIP are NOT diagnoses - these are lung injury patterns with clinical associations and correlations.  (Courtesy of Dr. Aryeh Fischer at the ARTHROS W. Virgina State Rheumatology Meeting)
  2. UIP (Usual interstitial pneumonia) is best diagnosed by HRCT; appears as honeycombing; and is the most common form of ILD. It is also the most common cause of ILD in rheumatoid arthritis and second most common in PSS and other CTD.
  3. NSIP (nonspecific interstitial pneumonitis): shows as ground glass opacities; most common ILD pattern in PSS and other CTD.  NSIP has better survival than UIP.
  4. Who should get HRCT after CXR and PFTs? Each of the following increase the likelihood of having significant ILD: consider in Men, smokers, CCP+, RA patients. CCP+ is independent risk factor for ILD.
  5. The majority of PSS patients will have ILD (fibrotic NSIP is most common). ILD is the leading cause of death in PSS.
  6. In 658 hospitalized PSS patients, there were 29 deaths. The risk factors associated with death was ascertained; - higher risk with high BUN, history of aspiration, low Hgb, non-SSc lung disease
  7. In an IBD cohort study, perioperative MTX use was not associated with an increase in post-operative  complications or sepsis in IBD pts having abdominal surgery. 
  8. Colchicine once daily is equivalent to twice daily dosing in preventing attacks with Familial Meditteranean Fever 
  9. A metanalysis of 4 RCT using rituximab (RTX) in Sjogren’s syndrome:  276 patients saw that RTX had no effect on Schirmers test, fatigue, ESSDAI & SF36 after 24 weeks.  
  10.  Surgical Management of Spinal Stenosis - To Fuse or Not To Fuse?
  11. Lupus Patients Genomically Stratified to Explain Treatment Responses 
  12. Population-Based TB Risk and Prevention with RA and Biologics
  13. A Rocky Start for Biosimilar Inflectra?
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings;; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.